Turning DNA data into action with **whole genome insights**

INOCRAS

DID YOU KNOW?



> 25% of cancer patients have complicated mutations (structural variations and/or variants in non-coding regions) that are often missed in standard panel sequencing and exome sequencing.*



10-20% of additional diagnoses of rare diseases were found by whole genome sequencing, compared to standard panel and exome sequencing.**

*Nature 578, 82–93 (2020).
https://doi.org/10.1038/s41586-020-1969-6
**Lionel, A. et al, Genetics in Medicine, April 2018.
Turro, E., Astle, W.J., Megy, K. et al, Nature, June 2020.
Ewans, L.J., Minoche, A.E., Schofield, D. et al., Nature, July 2022.

Contents

We Are Inocras	4
The Inocras Difference	6
Whole Genome Sequencing	7
Our Products	8
Inocras Digital Platform	10
Patient Success Stories	11

WE ARE INOCRAS

Unlock the new era of whole genome insights with Inocras

Inocras is on a mission to improve how the world diagnoses and treats genetically driven diseases. Specializing in cancer and rare diseases, our whole genome bioinformatics platform offers a comprehensive view of a person's genetic makeup, combined with actionable clinical insights for better patient care.

OUR PARTNERS

SAMSUNG LIFE SERVICE · Guide Genetics · ASAN Medical Center · ULTIMA GENOMICS · SCL (재)서울의과학연구소 Seoul Clinical Laboratories · DNAvisit

WHAT WE DO

- We perform whole genome sequencing to get a comprehensive view of the genome and identify pathogenic mutations
- Our patent-protected technology and proprietary bioinformatics pipeline enables us to interpret massive WGS data into actionable insights
- We specialize in cancer and rare diseasae diagnostics, with more than 15,000 patients served

WHO WE SERVE

Our goal is to provide user-friendly services with the power of WGS insights.

Patients

- WGS test report
- Clinical trial matching
- Genetic counseling
- End-to-end digital experience

Physicians

- WGS test report
- Clinical trial matching
- Expert support
- Digital ordering system

Researchers

- Fit-for-purpose research service menu
- Customized support with expert advisory
- Latest sequencing technology

THE INOCRAS DIFFERENCE

Where data, AI and care meet

Genome-based diagnostic solutions powered by AI
Our innovative whole genome services harness the power of advanced AI algorithms and extensive genomic datasets to offer insights into the genetic makeup of cancer and rare disease patients. By profiling the whole genome, CancerVision and RareVision may catch what other tests miss.

Powered by world-class bioinformatics
Our proprietary, high-performance bioinformatics pipeline was developed by medical and computer science experts, blending science and technology for world-class genomic insights.

Designed for cost, speed and quality
Our tests offer cost effectiveness, fast turnaround times, and 99% sensitivity, and are validated for clinical use.

Commitment to science, innovation, and patients
With over 30 collaborative research studies in partnership with academia and pharmaceutical partners, we are advancing the world's understanding of genomic science and improving patient health.

CLIA certified, CAP accredited
Our San Diego lab is CLIA certified and CAP accredited for WGS-based diagnostics. We are HIPAA compliant and trusted to handle sensitive patient genetic data.

What is Whole Genome Sequencing (WGS)?

Genetic testing has undergone waves of evolution, from biomarker hotspot panels (~10 genes), targeted panels (300-500 genes), to exome sequencing focusing on protein-coding areas (exons). Now, whole genome sequencing is available, which covers the whole genome including protein-coding (exons), non-coding (introns) and mitochondrial DNA.

Our advanced whole genome diagnostics platform offers a comprehensive view of a person's genetic makeup, with insights tailored to each individual's results.

TARGETED PANEL SEQUENCING



<0.1% genome-wide coverage

Limited number of point mutations

Limited copy number variations

Limited structural variations

WHOLE EXOME SEQUENCING



1-2% genome-wide coverage

Limited number of point mutations

Limited copy number variations

Limited structural variations

Non-coding areas not covered

WHOLE GENOME SEQUENCING



>99% genome-wide coverage

More point mutations identified

More accurate, genome-wide copy number variations

Genome-wide coverage of structural variations

Non-coding areas also covered



OUR PRODUCTS

Seeing cancer and rare disease from new angles

We combine cutting-edge bioinformatics with in-house clinical expertise to provide timely, accurate, and clinically meaningful insights.

Whether you're a provider with a patient seeking information about their cancer treatment options or navigating a diagnostic journey for a rare disease, or a researcher wanting to unlock the power of whole genome insights, CancerVision and RareVision are forging the future of personalized medicine.

CancerVision

Cancer profiling diagnostics solutions for patients with solid tumor cancers. Our test reduces the likelihood of false positives by ruling out benign variants in the tumor sample. It has shown high clinical utility in real-world setting.

- 2-in-one test: paried somatic-germline testing
- Liquid biopsy for cancer profiling with cfDNA* when tissue sample fails
- Target-enhanced whole-genome sequencing: an average of 40x depth WGS backbone with focused exploration of an average of over 500x depth for 500 key biomarker genes
- All types of alterations: single nucleotide variants (SNVs), small indel variants, large structural variants (SV) and copy number variants (CNV), including variants in non-coding regions
- Genome-wide signatures: our proprietary algorithms for Tumor Mutational Burden (TMB), Microsatellite instability (MSI), Homologous recombination deficiency (HRD), and more
- Germline WGS reports pathogenic germline variants according to ACMG guidelines
- Expert consultation available upon request (including Molecular Tumor Board)
- 2-week turnaround time**

*Circulating cell-free DNA (cfDNA) refers to extracellular DNA present in body fluid that may be derived from both normal and diseased cells.
**2 weeks from receipt of the tissue and blood samples at our lab.

RareVision

Shorten the diagnostic window for patients with rare diseases. We combine bioinformatics with in-house clinical expertise to provide timely, accurate, and clinically meaningful insights.

RareVision is a diagnostic solution for more than 7,000 rare diseases. Our internal study shows 23.6% additional rare disease cases detected with RareVision among the cases previously undiagnosed with other test methods (including targeted panel sequencing, whole exome sequencing).

- An average of-30x depth for whole genome sequencing, tested with more than 3,000 patients (over 6,000 cases including family members)
- Following ACMG/ClinGen guidelines and standards

- High clinincal utility: 30-50% positive diagnosis rate, depending on age group and disease criteria (on par with the best-in-class pipeline in the world)
- Expert consultation available upon request
- 2-week turnaround time*

*2 weeks from receipt of the and blood samples at our lab.

Our digital ordering platform is the first step to personalized care

The Inocras digital ordering platform connects patients with critical support on their cancer and rare disease journey, and we're walking with them every step of the way.



Easy-to-understand result reports with actionable findings: Our whole genome test unveils a comprehensive picture of a patient's genome, giving patients and providers critical findings for to inform next steps in care.

Genetic counseling and expert support: Patients have access to a genetic counselor to discuss and understand their test results. Providers have access to our in-house genomic experts (on demand) while our dedicated sales and medical teams are just a phone call away.

Clinical trial matching: We identify clinical trial matches based on patient biomarkers and other criteria allowing them to explore treatment options and saving providers time in finding the best matched clinical trials for their patients.



PATIENT SUCCESS STORIES

Breast cancer patient finds hope in new treatment options

Diagnosed with pancreatic cancer at age 40, Sarah had previously been successfully treated for breast cancer at 20. Several genetic tests, including a tissue panel test and hereditary cancer panel test, failed to reveal the root cause of her disease and why she got two different types of cancer at different points in her life.

The CancerVision test provided a breakthrough: it discovered Sarah had a genetic mutation in a gene called BRCA1. This mutation was present from Sarah's birth and contributed to her breast cancer by impairing her body's ability to repair DNA damages that could lead to other cancers.

The CancerVision findings identified more informed treatment options for Sarah and gave her a clearer picture of what was driving her cancer at a genetic level.

A family finds answers for perplexing symptoms

Andrew, a 1-year-old boy, was experiencing a myriad of perplexing symptoms, including decreased muscle tone, facial abnormalities, and a developmental delays. With the hope of finding answers, Andrew's provider ordered the RareVision test. The results revealed a change to his DNA that supported to a definitive diagnosis of a rare genetic disorder called Noonan syndrome. **This finding provided a roadmap for his future care that allowed his family to take proactive steps in managing his health and to make empowered family planning decisions.**

**While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual. Photos are not of the actual patients. These patient stories are based on collaborative research funded by Inocras.*

INOCRAS

INOCRAS.COM
6330 Nancy Ridge Drive, Suite 106
San Diego, CA 92121

IP25-0524